Menu

Following FDA OK, 23andMe to Expand Health Prediction

The personal genomics firm is ramping up its suite of disease-related genetic tests.

Oct 21, 2015
Kerry Grens

FLICKR, LEON BROCARDAfter putting a stop in 2013 to 23andMe offering health prediction tests to its consumers, the US Food and Drug Administration (FDA) in February gave the OK for the personal genomics firm to test for one genetic disease. Today (October 21), the company announced it will add 36 additional genetic tests to its health-prediction roster based on expanded FDA approval. The new service will cost $199.

“This isn’t going to get them too far, but maybe it’s a step along the path for them to get rebooted to where they were,” Eric Topol, a genomics professor at the Scripps Research Institute in La Jolla, California, who isn’t affiliated with the company, told The Wall Street Journal.

Nearly two years ago, 23andMe was asked to cease its health and disease tests over concerns about their accuracy. Since then it has only provided ancestry information. In February, the FDA gave the green light to test whether customers are a carrier for Bloom Syndrome. The company’s latest offerings include carrier tests for cystic fibrosis and sickle cell anemia.

“Part of what we tried to do over the last two years is take advantage of being off the market to redesign the entire experience,” Anne Wojcicki, cofounder and chief executive of 23andMe, told The New York Times.

“While FDA has approved carrier tests there still isn’t infrastructure to support the consumption of that information by consumers, and that’s where I have concerns,” Dietrich Stephan, a geneticist at the University of Pittsburgh Medical Center, said in a statement. “The other main point for consumers to be aware of is the issue of awareness and informed consent. Their genetic data and their self-reported survey data are being pushed to internal pharmaceutical development, and may be shared with external pharmaceutical partners outside of 23andMe. It’s legal and above board, but important for consumers to be aware of.”  

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.